

Roche

Pharmaceuticals

FACSIMILE TRANSMISSION

To:	Konata M. George	From:	Brian L. Buckwalter, Ph.D.
Co:	U.S. Patent & Trademark Office	email:	brian.buckwalter@roche.com
Fax #:	703-746-5201	Roche Biosciences	
Phone #:	703-308-4646	3401 Hillview Ave. A2-250	
Date:		Palo Alto, CA 94304-1397	
		Phone:	650-855-6995
Page # (with cover):	26	Fax:	650-855-5322
Message:			
<p>Examiner George,</p> <p>This is a draft of the response which we plan to file and which I would like to discuss with you in the telephone interview scheduled for Wednesday, January 29 at 1:00 EST. I will call you at the Office number listed above.</p> <p>Best regards, Brian L. Buckwalter</p>			

09/966,202

THE DOCUMENTS ACCOMPANYING THIS FACSIMILE TRANSMISSION MAY CONTAIN PRIVILEGED AND CONFIDENTIAL INFORMATION, AND ARE INTENDED ONLY FOR USE BY THE INDIVIDUAL OR ENTITY NAMED ON THIS TRANSMISSION SHEET. ANY DISCLOSURE, COPYING, OR DISTRIBUTION OR TAKING OF ANY ACTION BY A NON-INTENDED RECIPIENT IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS FACSIMILE IN ERROR, PLEASE TELEPHONE US (COLLECT) IMMEDIATELY SO THAT WE CAN ARRANGE RETURN OF THESE DOCUMENTS TO US AT NO COST TO YOU.

DRAFT**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re: Application of Paula Belloni.

:Group Art Unit: 1616

Appln. No.: 09/966,202

:Examiner: Konata M. George

Filed: September 26, 2001

For: METHODS FOR THE TREATMENT OF EMPHYSEMA
USING 13-*CIS*-RETINOIC ACIDAssistant Commissioner of Patents
Washington, D.C. 20231

SIR:

AMENDMENT AND RESPONSE

This Amendment responds to the Office Action dated October 30, 2002, with a shortened statutory period for response set to expire January 30, 2003. Please make the following amendments and take the accompanying remarks into consideration.

In the Title:

Please amend the title as follows:

METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF EMPHYSEMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE USING 13-*CIS*-RETINOIC ACID

In the claims:

Please cancel claims 2, 3, 4, 5 and 23.

Please amend claim 11 as follows:

11. (amended) A pharmaceutical composition suitable for treating a mammal suffering from emphysema comprising an amount of 13-*cis*-retinoic acid or a pharmaceutically acceptable salt, hydrate, solvate or prodrug thereof, and a pharmaceutically acceptable carrier, said amount being sufficient to alleviate at least one symptom of emphysema.

In claim 12, please replace "claim 11" with --claim 36--.

In claim 13, please replace "claim 11" with --claim 36--.

In claim 23, please replace "method" with --composition--.

In claim 29, please replace "a" with --an--.

In claim 30, please replace "a" with --an--.